{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:06Z","timestamp":1793896086479,"version":"4.8.0"},"reference-count":41,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Enthesitis\u2010related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category, primarily affecting entheses and peripheral joints. This study evaluated efficacy, safety, and pharmacokinetics of adalimumab versus placebo in patients with ERA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a phase III, multicenter, randomized double\u2010blind study in patients ages \u22656 to &lt;18 years with ERA treated with adalimumab (24 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , maximum dose 40 mg every other week) or placebo for 12 weeks, followed by up to 192 weeks of open\u2010label adalimumab. The primary end point was percent change from baseline in number of active joints with arthritis (AJC) at week 12. Samples were collected to determine adalimumab serum concentrations. Adverse events (AEs) were assessed throughout the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty\u2010six patients were randomized (31 adalimumab\/15 placebo). At baseline, mean age was 12.9 years, mean duration of ERA symptoms was 2.6 years, mean AJC was 7.8, and mean enthesitis count was 8.1. Mean percent change from baseline in AJC at week 12 was greater in the adalimumab group versus placebo (\u221262.6% versus \u221211.6%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039). Most secondary variables favored adalimumab versus placebo at week 12. Treatment response further increased with continued adalimumab therapy through week 52. Mean steady\u2010state adalimumab serum concentrations were 7.5\u201311.8 \u03bcg\/ml, similar to patients age \u22652 years with polyarticular JIA. AE rates were similar between placebo and adalimumab: any AE (53.3% versus 67.7%), serious AEs (0% versus 3.2%), and infectious AEs (20.0% versus 29.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adalimumab reduced signs and symptoms of ERA at week 12, with improvement sustained through week 52. The safety profile was consistent with previous adalimumab studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.22657","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:07:16Z","timestamp":1438214836000},"page":"1503-1512","source":"Crossref","is-referenced-by-count":99,"title":["A Randomized, Double\u2010Blind, Placebo\u2010Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis\u2010Related Arthritis"],"prefix":"10.1002","volume":"67","author":[{"given":"Rub\u00e9n","family":"Burgos\u2010Vargas","sequence":"first","affiliation":[{"name":"Hospital General de Mexico, Universidad Nacional Autonoma de Mexico Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley M. L.","family":"Tse","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[{"name":"Asklepios Klinik Sankt Augustin  Sankt Augustin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen L.","family":"Pangan","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago  Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Goss","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago  Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unnebrink","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland  Ludwigshafen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn K.","family":"Anderson","sequence":"additional","affiliation":[{"name":"AbbVie  North Chicago  Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty RE","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22181"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-6-18"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21174"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21850"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10444"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120642"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514043"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.941"},{"key":"e_1_2_7_11_1","first-page":"S578","article-title":"An open, observational, extension study of a three\u2010month, randomized, placebo\u2010controlled trial to assess the long\u2010term efficacy and safety of infliximab in juvenile\u2010onset spondyloarthritis (Jo\u2010Spa) [abstract]","volume":"58","author":"Burgos\u2010Vargas R","year":"2008","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_12_1","first-page":"2055","article-title":"Prolonged efficacy of etanercept in refractory enthesitis\u2010related arthritis","volume":"31","author":"Henrickson M","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21121"},{"key":"e_1_2_7_14_1","first-page":"424","article-title":"Long\u2010term outcome of anti\u2010tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis","volume":"32","author":"Hugle B","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_15_1","first-page":"1186","article-title":"Radiologic improvement of juvenile idiopathic arthritis enthesitis\u2013related arthritis following anti\u2013tumor necrosis factor\u2010\u03b1 blockade with etanercept","volume":"33","author":"Tse SM","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.03.008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0378-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110145"},{"key":"e_1_2_7_19_1","first-page":"S319","article-title":"Efficacy, safety, and tolerability of infliximab in juvenile\u2010onset spondyloarthropathies (JO\u2010SpA): results of the three\u2010month, randomized, double\u2010blind, placebo\u2010controlled trial phase [abstract]","volume":"56","author":"Burgos\u2010Vargas R","year":"2007","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4072"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203046"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq292"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110427"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2082-5"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2498-1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"e_1_2_7_31_1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett S","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400703"},{"key":"e_1_2_7_33_1","first-page":"1520","article-title":"Worldwide prevalence of juvenile arthritis: why does it vary so much?","volume":"29","author":"Manners PJ","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60363-8"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes004"},{"key":"e_1_2_7_36_1","first-page":"1069","article-title":"Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis: International League of Associations for Rheumatology","volume":"27","author":"Foeldvari I","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_7_37_1","first-page":"1377","article-title":"Epidemiology of juvenile idiopathic arthritis in Alsace, France","volume":"33","author":"Danner S","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_38_1","first-page":"229","article-title":"Focus on juvenile idiopathic arthritis according to the 2001 Edmonton revised classification from the International League of Associations for Rheumatology: an Italian experience","volume":"10","author":"Stabile A","year":"2006","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_39_1","first-page":"845","article-title":"Sulfasalazine for the management of juvenile rheumatoid arthritis","volume":"28","author":"Brooks CD.","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2744-6"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380618"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22657","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.22657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:53:32Z","timestamp":1759424012000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/acr.22657"],"URL":"https:\/\/doi.org\/10.1002\/acr.22657","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]}}}